8-K: PMI Reaffirms 2025 Full-Year EPS Forecast

Philip Morris International reaffirms its 2025 full-year diluted EPS forecast, projecting significant growth over 2024 adjusted figures.

Summary

• Philip Morris International (PMI) Chief Executive Officer, Jacek Olczak, will address investors at the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025.
• PMI reaffirms its 2025 full-year reported diluted EPS forecast of $7.39 to $7.49, as announced on October 21, 2025.
• Excluding a total 2025 adjustment of $0.07 per share, this forecast represents a projected increase of 13.5% to 15.1% compared to adjusted diluted EPS of $6.57 in 2024.
• Further excluding a favorable currency impact of $0.10 per share, the forecast represents a projected increase of 12.0% to 13.5% compared to adjusted diluted EPS of $6.57 in 2024.
• The underlying assumptions for this forecast remain unchanged from those communicated in PMI's Third-Quarter 2025 earnings release.
• PMI's smoke-free products are available in over 100 markets and were used by over 41 million legal-age consumers globally as of June 30, 2025.
• The smoke-free business accounted for 41% of PMI's first-nine months 2025 total net revenues.
• Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products.

Sentiment

Score: 7

Explanation: The reaffirmation of a strong EPS forecast and continued progress in the smoke-free category are positive indicators of stable performance and strategic execution. However, the extensive list of inherent industry risks and the forward-looking nature of the statements temper the overall sentiment, suggesting caution despite positive projections.

Positives

• Reaffirmation of the 2025 full-year reported diluted EPS forecast of $7.39 to $7.49.
• Projected increase of 13.5% to 15.1% in adjusted diluted EPS (excluding 2025 adjustments) compared to 2024 adjusted diluted EPS of $6.57.
• Projected increase of 12.0% to 13.5% in adjusted diluted EPS (excluding currency impact and 2025 adjustments) compared to 2024 adjusted diluted EPS of $6.57.
• Smoke-free products are used by over 41 million legal-age consumers around the world as of June 30, 2025.
• The smoke-free business contributed 41% of PMI's first-nine months 2025 total net revenues, indicating successful portfolio transformation.
• U.S. FDA has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches, and versions of PMI's IQOS devices and consumables.
• Versions of IQOS devices and consumables and General snus obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA.

Negatives

• The forecast includes various adjustments such as restructuring charges, impairment of goodwill and other intangibles, amortization of intangibles, Germany excise tax classification litigation charge, and tax items.
• Forward-looking statements are subject to risks, uncertainties, and inaccurate assumptions, which could cause actual results to vary materially.

Risks

• Excise tax increases and discriminatory tax structures.
• Increasing marketing and regulatory restrictions that could reduce competitiveness, eliminate the ability to communicate with adult consumers, or ban certain products.
• Health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke.
• Litigation related to tobacco and/or nicotine use and intellectual property.
• Intense competition.
• Effects of global and individual country economic, regulatory, and political developments, natural disasters, and conflicts.
• Impact and consequences of Russia's invasion of Ukraine.
• Changes in adult smoker behavior.
• Impact of natural disasters and pandemics on PMI's business.
• Lost revenues as a result of counterfeiting, contraband, and cross-border purchases.
• Governmental investigations.
• Unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds.
• Adverse changes in applicable corporate tax laws.
• Recent and potential future tariffs imposed by the U.S. and other countries.
• Adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for electronic devices.
• Integrity of information systems and effectiveness of data privacy policies.
• Unsuccessful attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes.
• Inability to successfully introduce new products, promote brand equity, enter new markets or improve margins through increased prices and productivity gains.
• Inability to expand brand portfolio internally or through acquisitions and the development of strategic business relationships.
• Inability to attract and retain the best global talent.
• Inability to successfully integrate and realize the expected benefits from recent transactions and acquisitions.
• Lower predictability of smoke-free products performance.

Future Outlook

PMI reaffirms its 2025 full-year reported diluted EPS forecast, projecting significant growth over 2024 adjusted figures, with underlying assumptions remaining unchanged. The company continues its long-term ambition to expand into wellness and healthcare areas, aiming to enhance life through seamless health experiences, while actively delivering a smoke-free future by transitioning its portfolio away from cigarettes.

Management Comments

• Jacek Olczak, Chief Executive Officer, will address investors at the Morgan Stanley Global Consumer & Retail Conference.

Industry Context

PMI is positioning itself as a 'Global Smoke-Free Champion,' actively transitioning its portfolio away from traditional cigarettes towards heat-not-burn, nicotine pouch, and e-vapor products. This strategy aligns with broader global health trends and increasing regulatory pressure on traditional tobacco, aiming to capture market share in the reduced-risk product category. The significant investment in smoke-free products and the FDA authorizations highlight a strategic pivot to maintain relevance and growth in a changing consumer landscape, differentiating PMI from companies solely focused on traditional tobacco products.

Comparison to Industry Standards

• PMI's focus on smoke-free products, with 41% of first-nine months 2025 net revenues from this segment, demonstrates a leading position in the tobacco industry's transition to reduced-risk alternatives, comparable to efforts by competitors like British American Tobacco (BAT) and Japan Tobacco International (JTI) who are also investing heavily in next-generation products.
• The FDA's Modified Risk Tobacco Product (MRTP) authorizations for IQOS and General snus are significant regulatory milestones, setting a high bar for scientific substantiation that few other companies in the nicotine industry have achieved, distinguishing PMI's regulatory success.
• The $14 billion investment since 2008 in smoke-free product development underscores a substantial commitment to innovation, a scale of investment that positions PMI among the top innovators in the consumer goods sector for product transformation, exceeding many peers' R&D spending in this specific area.

Legal Proceedings

• Litigation related to tobacco and/or nicotine use and intellectual property is identified as a continuing business risk.
• Governmental investigations are identified as a continuing business risk.

Stakeholder Impact

• Shareholders: The reaffirmed strong EPS forecast and strategic pivot to smoke-free products could positively impact long-term shareholder value and confidence.
• Consumers: Continued availability and development of scientifically substantiated smoke-free products offer alternatives for adult smokers who would otherwise continue to smoke.
• Employees: Ongoing investment in new product categories and scientific capabilities suggests continued innovation and potential for new roles and skill development within the company.
• Regulatory Authorities: Compliance with FDA authorizations and significant investment in scientific substantiation demonstrate adherence to regulatory standards and a commitment to responsible product development.

Next Steps

• PMI CEO Jacek Olczak will present at the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025.
• A live audio webcast of the presentation and Q&A session will be available, with an archived copy accessible for six months after the event.
• PMI will continue to update any forward-looking statements in the normal course of its public disclosure obligations.

Key Dates

Recommendation

The reaffirmation of the 2025 EPS forecast, coupled with strong growth projections and continued momentum in the smoke-free category, indicates a stable and strategically sound company performing as expected. However, the extensive list of inherent industry risks, including regulatory pressures, litigation, and currency fluctuations, suggests that while the company is performing as expected, there are significant headwinds that could impact future performance. The stock is likely priced to reflect these known factors, making a 'hold' recommendation appropriate for investors seeking stability with a watchful eye on risk mitigation and the success of the smoke-free transition.

Keywords

Philip Morris International, PMI, PM, EPS forecast, smoke-free products, IQOS, ZYN, nicotine pouches, tobacco alternatives, consumer goods, Morgan Stanley Conference, financial outlook, investor relations, SEC filing, 8-K, corporate governance, risk management